Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Analysis: U.S. drugmakers, bracing for price cuts, shift election support toward Democrats

10/29/2020 | 05:18am EST
FILE PHOTO: A Pfizer sign is pictured at their Headquarters in the Manhattan borough of New York City

NEW YORK (Reuters) - The U.S. pharmaceutical industry, long a supporter of Republicans, is giving almost half its political donations to Democratic candidates in this year's election, as companies look to fend off a threat to drug prices if Democrats gain power.

So far this year, industry-run political action committees (PACs) have divided about $13 million between the two major U.S. political parties, with 54% to Republicans and 46% to Democrats, according to data from the Center for Responsive Politics (CRP) reviewed by Reuters.

That is a stark shift from 2016, when nearly two thirds of industry campaign donations went to Republicans. The industry moved less dramatically toward Democrats in 2018 during the congressional elections.

Senior pharmaceutical executives lean Republican, while workers' donations skew toward Democrats and largely supported Democratic presidential challenger Joe Biden, data shows. Biden leads Republican President Donald Trump in national opinion polls in the last week before next Tuesday's election.

The industry-level shift, based on support from non-profit political action committees affiliated with drug companies, funded by employees and directed by executives and staff, reflects a consensus that Democrats will expand their hold on the House of Representatives and may gain control of the Senate.

Pharma companies aim to build close relationships with politicians who are likely to be in power, and usually avoid presidential races and close congressional campaigns, said an industry executive who was not authorized to speak publicly.

He and other industry sources said drugmakers were aiming to head off efforts by Democrats to slash drug prices paid by Medicare, a government-run health insurance program for seniors, industry sources said.

"They are interested in funding whoever they think might win," said David Gartner, professor of law at Arizona State University who focuses on U.S. healthcare policy.

That may mean contributing to lawmakers who disagree with the industry.

A plan earlier this year that was stymied by Senate Republicans would have reduced pharma revenues from Medicare by more than $300 billion by the end of the decade, the Congressional Budget Office calculated.

Trump, in a departure from his party, has issued several executive orders meant to cut drug prices, but experts say their impact will be limited by legal and other problems and that a Democratic Congress could mount a more serious challenge.

SHIFT IN SUPPORT

The biggest pharma PAC donations so far this year have come from Pfizer Inc, Amgen Inc, Abbvie Inc and Johnson & Johnson, which all shifted support toward Democrats between 2016 and 2020, records show. Pfizer's change was the most dramatic, giving 63% of its funds to Republicans in 2016 and 51% in 2020.

In the 2018 election cycle, in which Democrats took control of the House, some 57% of the industry's more than $17 million in donations went to Republicans. Industry PACs leaned Republican during each federal election in the past eight years by varying margins, political donation data shows.

Pharma industry employees, who are concentrated in Democratic-leaning hubs including California, Massachusetts and New York, consistently tilt Democratic. They are supporting Biden at a rate of about 4 to 1 or roughly $6 million to $1.5 million in donations, data show.

Top executives, however, lean Republican. A Reuters review of top pharma executives showed a nearly 2-1 split in favor of Republicans, with more than $150,000 going to Republicans and around $75,000 to Democrats. Individual donations tend to reflect personal political leanings, experts said.

A broader measure of individual donations that covers the entire healthcare industry and includes donations to super PACs, which can take unlimited funds and often attract wealthy donors, shows Trump receiving about $60 million to Biden's $54 million, according to CRP data.

There are broad concerns that the Trump administration is inserting political issues into regulatory decisions, which could indirectly hurt the drug industry's reputation.

But Aaron Kesselheim, a Harvard Medical School specialist in U.S. healthcare policy, said: "I don't really think that has much to do with political donations, which are trying to curry favor with the party that seems to be ascendant."

(Reporting by Carl O'Donnell; Editing by Peter Henderson and Peter Cooney)

By Carl O'Donnell


© Reuters 2020
All news about AMGEN INC.
04:00pCOVID R&D Alliance launches trial of Amgen, UCB, Takeda drugs
RE
04:00pCovid r&d alliance launches trial of amgen, ucb, takeda drugs for hospitalize..
RE
11/28AMGEN : What's Next For U.S. Biosimilar Litigation
AQ
11/26AMGEN : to Present At The Evercore ISI Virtual HealthCONx Conference
AQ
11/25AMGEN : To Present At The Evercore ISI Virtual HealthCONx Conference
PR
11/25AMGEN : On Pace for Eight-Day Losing Streak, Longest Since October 2017 -- Data ..
DJ
11/24AMGEN : to Transition Development and Commercial Rights for Omecamtiv Mecarbil a..
AQ
11/23AMGEN : Ending Heart-Failure Collaboration With Cytokinetics
DJ
11/20ENTERA BIO LTD : Announces Third Quarter 2020 Financial Results and Provides Cli..
AQ
11/20AMGEN : BeiGene Announces the Approval of XGEVA in China for the Prevention of S..
AQ
More news
Financials (USD)
Sales 2020 25 380 M - -
Net income 2020 7 038 M - -
Net Debt 2020 18 313 M - -
P/E ratio 2020 18,8x
Yield 2020 2,88%
Capitalization 129 B 129 B -
EV / Sales 2020 5,81x
EV / Sales 2021 5,44x
Nbr of Employees 23 400
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 251,24 $
Last Close Price 222,04 $
Spread / Highest target 36,9%
Spread / Average Target 13,2%
Spread / Lowest Target -16,7%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman, President & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
Peter H. Griffith Chief Financial Officer
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.-7.89%130 877
JOHNSON & JOHNSON-1.28%379 086
ROCHE HOLDING AG-3.66%285 972
PFIZER INC.0.30%206 939
NOVARTIS AG-11.80%203 829
MERCK & CO., INC.-12.19%202 049